Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
about
Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B.If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia.In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
P2860
Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Population pharmacokinetics of ...... ents with severe hemophilia B.
@en
Population pharmacokinetics of ...... ents with severe hemophilia B.
@nl
type
label
Population pharmacokinetics of ...... ents with severe hemophilia B.
@en
Population pharmacokinetics of ...... ents with severe hemophilia B.
@nl
prefLabel
Population pharmacokinetics of ...... ents with severe hemophilia B.
@en
Population pharmacokinetics of ...... ents with severe hemophilia B.
@nl
P2093
P2860
P921
P356
P1476
Population pharmacokinetics of ...... ents with severe hemophilia B.
@en
P2093
A Feussner
D Bensen-Kennedy
E Santagostino
P2860
P304
P356
10.1111/JTH.13444
P577
2016-08-11T00:00:00Z